Healthcare Sector

Indian Benchmark indices ended sharply lower on June 23, 2026, as a 10% crash in South Korea's Kospi, weakness in IT stocks following Accenture's cautious outlook, and renewed concerns over higher US interest rates triggered broad-based selling. Nifty fell 278.80 points to 23,824.10, while Sensex declined 893.39 points to 76,200.68. Metal and IT stocks led losses, while Pharma emerged as the lone sectoral gainer amid defensive buying.

Indian benchmark indices extended gains on June 22, 2026, as easing geopolitical tensions, falling crude oil prices, strong buying in Reliance Industries after its AGM, recovering IT stocks, and robust foreign investor inflows supported market sentiment. Nifty closed above 24,100, Sensex rose nearly 300 points, and Pharma, Healthcare, Media, and Oil & Gas sectors emerged as top performers.

The Indian stock market extended its winning streak on June 17, 2026, as Nifty closed above the crucial 24,000 mark and Sensex gained 347 points. Defence stocks emerged as top performers following record domestic defence production in FY26, while lower crude oil prices, hopes of a US-Iran peace deal, and positive global cues supported broad-based buying across sectors.

Apollo Hospitals Enterprise Ltd shares touched a new 52-week high of ₹8,330 after the company reported robust Q4 FY26 results, supported by strong profit growth, higher hospital occupancy, improved operating margins, and positive healthcare demand trends. Investor sentiment also strengthened following the Cloudnine deal, merger approval, and dividend announcement.

Indian benchmark indices ended marginally lower on May 21, 2026, with Nifty closing near 23,654 and Sensex slipping 135 points amid concerns over RBI rate hikes, weak manufacturing PMI, rising crude oil prices, rupee weakness, and renewed FII selling. Defence and Realty stocks supported the market, while IT, FMCG, and Media remained under pressure.

Biocon is undergoing a strategic transformation with succession planning, appointing Claire Mazumdar as a likely successor, while strengthening biosimilars, restructuring operations, and advancing innovation-led biotech growth.

Healthcare funds can be defensive, while growing at a rapid pace during selective phases of its life cycle

According to reports, the USFDA made various observations concerning Sun Pharma. First, the company did not take appropriate safeguards to avoid API contamination.

According to a business announcement, net profit increased by 79% to ₹909 Crore in the fourth quarter of FY24, from ₹506 Crore in the same period in FY23.

The total net profit for the fiscal year ended March 31, 2024 was ₹1,656 Crore, up from ₹1,245 Crore the previous year, according to the business.